8 results about "Biliary atresia" patented technology

The invention relates to a pharmaceutical formulation, e.g. a paediatric formulation, of odevixibat, which comprises a plurality of small particles. The formulation may be used in the treatment of liver diseases such as bile acid-dependent liver diseases, and particularly cholestatic liver diseases such as biliary atresia, progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome (ALGS) and paediatric cholestatic pruritus. The invention also relates to a process for the preparation of the pharmaceutical formulation.

The present application relates to the technical field of vascular interventional treatment instruments, and discloses a system and method for the selective laser ablation of restenosis after the treatment of Budd-Chiari syndrome, comprising a controller, a pulse emission module and a reference element built into a catheter, the system is based on the reference element for periodic self-calibration, collects and processes the associated photoacoustic signals to identify the tissue type, and then realizes the selective ablation of the diseased tissue and the boundary self-stop when the healthy tissue is touched. The present application converts the traditional open-loop energy delivery into a closed-loop self-control process with real-time information interaction capability, so that the ablation operation end can in-situ perceive the tissue boundary and realize autonomous stop, thereby avoiding the problem of damaging the healthy tissue due to uncontrollable energy application, improving the safety of the operation, and having the advantages of high precision, few complications, repeatable treatment and the like.

The invention relates to the technical field of vascular interventional therapy instruments, and discloses an excimer laser ablation system and method for restenosis after Budd-Chiari syndrome interventional therapy, the excimer laser ablation system comprises a controller, a pulse transmitting module and a reference element arranged in a catheter, and the system performs periodic self-calibration based on the reference element; according to the method, associated photoacoustic signals are collected and processed to identify tissue types, selective ablation of lesion tissues and boundary self-stop when healthy tissues are touched are further achieved, traditional open-loop energy delivery is converted into a closed-loop self-control process with real-time information interaction capacity, and the method has the advantages of being simple in structure, convenient to operate and high in practicability. The ablation operation tail end can sense the tissue boundary in situ and achieve automatic stopping, so that the problem that healthy tissue is damaged due to uncontrollable energy application is solved, the safety of an operation is improved, and the advantages of being high in precision, few in complication, capable of achieving repeated treatment and the like are achieved.

The application relates to the field of biological medicine, and discloses application of folic acid in prevention, diagnosis and treatment of genetic, infectious or allergic diseases. The application finds that the folic acid can achieve the prevention and treatment effects on the genetic, infectious or allergic diseases by improving inflammation, regulating iron ion metabolism, correcting intestinal flora disorder, reducing liver / intestinal tissue damage, inhibiting expression of inflammatory factors and promoting expression of Nox2. Meanwhile, the application provides application of one or more of the folic acid, S100a8, S100a9, Nox2 and IFN-gamma as a diagnostic or auxiliary diagnostic marker of biliary atresia. Meanwhile, the application provides the folic acid or a derivative thereof, which is prepared into food, a nutritional preparation or a medicine and applied to children or adults, so as to achieve the purposes of preventing and treating biliary atresia, cholangitis, jaundice, infectious diseases, intestinal diseases and diseases caused by abnormal folic acid metabolism.

The invention discloses a preparation method and application of exosome-loaded Cas13d-RNP, and belongs to the technical field of biliary atresia research. The method comprises the following steps: extracting exosomes: culturing human bile duct cells H69 in a DMEM / F12 culture medium until the cell density reaches 90%, collecting supernatant of the culture medium, and extracting the exosomes by an ultracentrifugation method; cas13d-RNP loading: the Cas13d protein and crRNA are mixed for 15 minutes at the room temperature, Cas13d-RNP is obtained, the exosome and the Cas13d-RNP are mixed, and the Cas13d-RNP is loaded into the exosome in a circulating freezing and thawing mode. According to the invention, Cas13d-RNP is accurately delivered through the exosome vector, specific targeting is carried out on bile duct cell CTGF mRNA, and expression of fibrosis-related factors in bile duct cells is significantly reduced. Compared with traditional medicine treatment, bile duct reaction and fibrosis processes can be more effectively inhibited. As a natural vector, the exosome has the advantages of low immunogenicity and high delivery efficiency, and immunoreactions possibly caused by a traditional virus vector are reduced.

The invention belongs to the technical field of biological medicine, and particularly relates to a biliary atresia differential diagnosis and prognosis marker and application thereof. The invention provides the application of the KRT17 expression level as a biliary atresia differential diagnosis and prognostic marker for the first time. KRT17 as a single marker has a relatively high diagnostic value (AUC = 0.880) for BA, the efficiency of KRT17 is superior to all conventional clinical liver function indexes, and when KRT17 is combined with alanine aminotransferase for use, the diagnostic accuracy can be further improved to AUC = 0.904, the KRT17 and CX3CL1 are optimally combined, and the AUC value is as high as 0.938. According to the technology, KRT17 is used as a novel biliary atresia differential diagnosis marker, the defects of an existing differential diagnosis system can be made up to a certain degree, the KRT17 is specifically and highly expressed in biliary atresia liver bile duct epithelial cells, normal control and disease control are not expressed, and therefore more accurate differential diagnosis can be provided clinically.

The invention belongs to the technical field of biological medicines, and particularly relates to application of parinumod in preparation of a medicine for treating biliary atresia. The invention discovers the treatment application of the S100A8 / A9 inhibitor in biliary atresia for the first time. The method comprises the following steps: inducing the formation of BA by intraperitoneal injection of RRV within 24 hours after a BALB / c newborn mouse is born, and after the RRV is injected from the intraperitoneal cavity, from the second day, injecting an S100A8 / A9 inhibitor Paquinimod (dosage: 50 mg / kg) into the intraperitoneal cavity of the mouse once every other day until the twelfth day. It can be observed that the survival time of the BA mouse treated by Paquinimod is prolonged, the jaundice symptom is relieved, the liver function index is obviously improved, and the infiltration number of inflammatory cells around the hepatic bile duct is obviously reduced. The invention provides a new potential target and a treatment strategy for treatment of BA.

This invention belongs to the field of biomedical technology, specifically relating to the application of spermine in the preparation of drugs for treating biliary atresia. This invention is the first to verify, through animal experiments (RRV mouse model), that spermine has a clear therapeutic effect on biliary atresia, achieving common bile duct recanalization and significantly reducing liver inflammation. Spermine itself possesses multiple functions including antioxidant, anti-inflammatory, and direct JAK1 inhibition, potentially working synergistically through multiple mechanisms such as mitigating initial damage and regulating immune responses, providing a more comprehensive pathological intervention than single-target inhibitors. Furthermore, spermine, as a known compound, has low production costs, and its application will greatly improve the accessibility of treatment.